Evidence map›Paper›PMID 41388837›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2025

Plasma placental growth factor as a susceptibility biomarker for longitudinal cognitive change.

Anna M VandeBunte, Emily W Paolillo, Jason D Hinman, Rowan Saloner, Molly Olzinski, Shubir Dutt, Claire J Cadwallader, Valentina E Diaz, Savannah Hallgarth, Julio C Rojas and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. New perspectives on VEGF signalling in Alzheimer's disease.Brain pathology (Zurich, Switzerland) · 2026
    Review
  2. Plasma placental growth factor as a susceptibility biomarker for longitudinal cognitive change.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Anna M VandeBunteMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.ORCID 0000-0002-5167-3358
Emily W PaolilloMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Jason D HinmanDavid Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California, USA.
Rowan SalonerMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Molly OlzinskiMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Shubir DuttMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Claire J CadwalladerMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Valentina E DiazMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Savannah HallgarthMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Julio C RojasMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Pauline MaillardDepartment of Neurology and Center for Neuroscience, University of California, Davis, Davis, California, USA.
Kaitlin B CasalettoMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.
Joel H KramerMemory and Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, California, USA.

Funding

Mechanisms of Executive Decline in Normal AgingR01AG032289 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Kaitlin B Casaletto, JOEL H KRAMER · 2009 to 2026
$8.3M
Unraveling the intersection of synaptic biology, lifestyle, and cognitive resilienceR01AG072475 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CASALETTO, KAITLIN B · 2021 to 2025
$4.3M
Effects of chronic inflammation on brain structure and functionR01AG048234 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2015 to 2019
$3.2M
Novel Imaging and Biofluid Biomarkers of Small Vessel Cerebrovascular DiseaseUF1NS100608 · NINDS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI KRAMER, JOEL H · 2021 to 2021
$2.5M
Passive digital phenotyping for capturing real-world neurobehavior in neurodegenerative diseaseK23AG084883 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Emily Paolillo · 2024 to 2026
$592k
Deciphering the molecular landscape of frontotemporal lobar degeneration: A network-based proteomic approachK23AG090757 · NIA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Rowan Saloner · 2025 to 2026
$400k
Alzheimer's Association AARF-22-974065Alzheimer's Association AARF-23-1145318Alzheimer's Association AARG-20-683875AlzOutAmerican Academy of NeurologyAmerican Brain FoundationAssociation for Frontotemporal Lobar DegenerationJohn Douglas French Alzheimer's FoundationLarry L. Hillblom Foundation 2018-A-006-NETLarry L. Hillblom Foundation 2024-A-001-CTRNew Vision ResearchNew Vision Research CCAD 2024-001-1NIA NIH HHS K23 AG084883NIA NIH HHS K23 AG090757NIA NIH HHS R01 AG032289NIA NIH HHS R01 AG048234NIA NIH HHS R01 AG072475NIH-NIA K23AG084883NIH-NIA R01AG032289NIH-NIA R01AG048234NIH-NIA R01AG072475NIH-NIA UF1NS100608NINDS NIH HHS UF1 NS100608
6 · The paper itself

Abstract

introductionCurrent biomarkers used to assess cerebrovascular pathology largely reflect end-stage disease, and more sensitive biomarkers are needed. We examined the role of baseline placental growth factor (PlGF) as a susceptibility biomarker for the progression of white matter injury and longitudinal cognitive decline.

methodsA total of 272 functionally intact older adults completed baseline blood draws, with plasma analyzed for PlGF (Meso Scale Discovery), and longitudinal neuroimaging and neuropsychological testing. A subset of 110 participants (n = 110) had banked plasma assayed on a different biomarker platform (NULISAseq) to evaluate replicability.

resultsHigher baseline PlGF was associated with steeper declines in memory and processing speed. Elevated baseline PlGF also associated with greater baseline white matter hyperintensities and lower global fractional anisotropy (FA), but not white matter or FA trajectories. DISCUSSION: Elevated baseline plasma PlGF associated with faster declines in cognition even among functionally intact older adults across two biomarker platforms. Our findings highlight PlGF as a potential susceptibility/risk biomarker of vascular-related cognitive decline. HIGHLIGHTS: Higher plasma placental growth factor (PlGF) concentrations relate to greater baseline white matter injury. Elevated baseline plasma PlGF associates with steeper cognitive decline over time. PlGF may represent an upstream biomarker of endothelial-related cognitive decline.

Indexed as

Cognitive AgingCognitive DysfunctionPlacenta Growth FactorAgedBiomarkersCognitionDiffusion Tensor ImagingDisease SusceptibilityFemaleHumansMaleNeuropsychological TestsWhite MatterBiomarkersPGF protein, humanPlacenta Growth Factoragingcerebrovascular biomarkersendothelial dysfunctionfluid biomarkersvascular‐related cognitive impairmentwhite matter health

Identifiers

PMID41388837
PMCPMC12701522

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.